SCHEDULE: Bank of Montreal Discloses Akari Therapeutics Stake

Bank of Montreal, through its subsidiaries, has reported beneficial ownership of 5.71% of Akari Therapeutics Plc's ordinary shares as of June 30, 2026.

Summary

• Bank of Montreal, along with its subsidiaries Bank of Montreal Holding Inc. and BMO Nesbitt Burns Inc., has filed a Schedule 13G.
• This filing indicates beneficial ownership of 8,000,000,000 ordinary shares of Akari Therapeutics Plc.
• This ownership represents 5.71% of the class of securities.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• The reporting persons have shared power to vote and shared power to dispose of these securities.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without indicating new strategic initiatives or financial performance.

Positives

• Significant institutional ownership by a major financial institution like Bank of Montreal can sometimes be interpreted as a sign of confidence in the company's long-term prospects, although this filing is purely informational.
• The filing clarifies the ownership structure, providing transparency to the market regarding a substantial shareholder.

Negatives

• The filing does not provide any information regarding the company's financial performance, strategic direction, or operational updates, which are crucial for investment decisions.
• The large number of shares reported (8,000,000,000) could represent a significant portion of the total outstanding shares, but without knowing the total float, the exact impact is unclear.

Risks

• The filing does not explicitly mention any risks associated with Akari Therapeutics Plc. The primary risk is the lack of detailed operational or financial information within this specific filing.
• Potential for future market impact if Bank of Montreal decides to significantly alter its stake, though this filing does not suggest such intentions.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Akari Therapeutics Plc's future performance.

Management Comments

• Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act) with any other person as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the issuer or otherwise with respect to the issuer or any securities of the issuer or (ii) a member of any syndicate or group with respect to the issuer or any securities of the issuer.
• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors crossing certain ownership thresholds. This filing indicates a significant institutional presence in Akari Therapeutics Plc, but without further context on the company's operations or market position, its broader industry implications are limited.

Comparison to Industry Standards

• This filing is a standard Schedule 13G disclosure, which is a regulatory requirement for significant beneficial ownership. The specific percentage (5.71%) and number of shares (8,000,000,000) are unique to this company and reporting entity.
• Industry standards for institutional ownership vary widely by sector. For a biotechnology or pharmaceutical company like Akari Therapeutics, a 5.71% stake by a major financial institution is a notable holding.

Stakeholder Impact

• Shareholders: Increased transparency regarding a significant institutional shareholder may influence market perception, but the filing itself does not directly impact share value.
• Creditors: No direct impact indicated.
• Employees: No direct impact indicated.
• Suppliers/Customers: No direct impact indicated.

Next Steps

• Akari Therapeutics Plc may need to monitor its shareholder register for significant changes.
• Bank of Montreal and its subsidiaries will continue to report any further changes in beneficial ownership as required by regulations.

Key Dates

Keywords

Akari Therapeutics, Bank of Montreal, Schedule 13G, Beneficial Ownership, Ordinary Shares, Institutional Investor, Shareholder